Navigation Links
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
Date:12/20/2013

e inhibitors in patients with multiple myeloma at the 2013 Annual Meeting of the American Society of Hematology. Michael Needle, MD, Chief Medical Officer of Array BioPharma, stated, "Multiple myeloma remains an incurable disease, with a significant unmet medical need in patients who are relapsed/refractory to IMiDs and proteasome inhibitors. Filanesib is a first-in class drug in myeloma that is well tolerated and has shown very encouraging clinical activity in heavily pretreated patients who have limited therapeutic options. Furthermore, we are excited about the potential of our patient selection marker, AAG, which should help us identify which patients have the best chance to benefit from receiving filanesib." The Full Research Report on Array BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e048_ARRY

--

Lexicon Pharmaceuticals, Inc. Research Report

On December 3, 2013, Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). The Company informed that the primary endpoint of this study was the change in stool consistency averaged from baseline to day 28. Pablo Lapuerta, M.D., Chief Medical Officer of Lexicon Pharmaceuticals, stated, "While LX1033 showed similar improvements in stool consistency as compared to the placebo patients who completed the study, there were positive effects on abdominal pain in the treated group that warrant further study. While this initial Phase 2a study was underway, we completed long-term toxicology studies that would allow us to conduct a Phase 2b study at doses informed by the current results and with
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
2. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
3. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
4. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
5. Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 (extended-release topiramate) In Epilepsy Patients With Refractory Partial-Onset Seizures
6. Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
7. Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
8. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
9. Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel for Treatment of Painful Diabetic Neuropathy
10. Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer
11. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... George Products Company, Inc. has announced the addition ... OASIS Inspection Systems. Florida Metrology, based ... OASIS Inspection Systems is a line of highly accurate ... control departments across the United States. Tim Row of ...
... Sutro Biopharma, a biopharmaceutical company developing both ... properties, today announced that it has appointed Trevor ... Hallam will lead Sutro,s ongoing efforts in the ... platform for the research and development of novel ...
Cached Medicine Technology:Florida Metrology To Distribute OASIS Inspection Systems 2Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer 2
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2
... , BETHEL, Conn., Dec. 4 MedClean Technologies, Inc. (OTC Bulletin ... stock purchase agreement with Socius Capital Group, LLC, a Delaware limited ... LLC. Pursuant to the Purchase Agreement, MedClean will receive up to ... up to 750 shares of its Series C Preferred Stock, in ...
... , UNION, N.J., Dec. 4 ... its specialty anatomic pathology services with the launch of ... company,s expansion from a regional laboratory to a leading ... full range of specialties including gastroenterology, urology and now ...
... , OKLAHOMA CITY, Dec. 4 PD-Rx Pharmaceuticals, Inc. (Pink Sheets: ... September 30, 2009, a 24% decrease over the same period last ... $133,681 and $80,402, respectively, each a 70% decrease over the same ... pharmacy sector sales. This trend is expected to continue throughout ...
... SEATTLE, Dec. 4 The National Cancer Institute has awarded a ... become the nation,s sole operator of its Cancer Information Service Contact ... Hutchinson Center - nearly tripling the size of its current CIS ... scheduled for March 15, 2010. The Seattle CIS center will remain ...
... School of Medicine (BUSM) researchers at the Slone Epidemiology Center ... have a reduced incidence of uterine leiomyomata (fibroids). This report, ... current issue of the American Journal of Epidemiology . ... are two to three times more common among black women ...
... ... support Joint Commission initiative to establish standards for language access in healthcare organizations. ... ... information, drug data solutions, and patient education materials for healthcare institutions, understands the ...
Cached Medicine News:Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Researchers find increased dairy intake reduces risk of uterine fibroids in black women 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... (hepatitis C virus) is a Microparticle Enzyme ... anti-HCV IgG to HCV recombinant proteins in ... EDTA, sodium heparin, lithium heparin, sodium citrate ... with other laboratory results and clinical information, ...
... MasterControl architecture is the power behind ... provides all the essential building blocks ... management system to boost operational efficiency, ... with regulatory and quality standards. Click ...
... systems are automated, easy to operate and ... outside environment by flexible snap-seal pockets which ... viral contamination of the water. Offered in ... can also accommodate bags of various sizes. ...
Medicine Products: